Interim Chief Executive Officer

Seasoned biotech CEO with over 20 years of experience in leading platform-based ventures to phase II clinical stage, specializing in immuno-oncology and AI diseases

Successfully managed private biotech companies, raising more than €15 million in equity financing and achieving a 5x equity deal exit with strategic partnerships

Holds a Doctorate in Medicine and an MBA, with executive training in corporate finance and private equity, and a Corporate Director Certification

Global work proficiency with experience in the USA, EU, Japan, Canada, MEA, China, and Latam, demonstrating international mobility and adaptability

Conducted due diligence for a German investor on a potential spin-off focused on CAAR-T cell therapies and T-cell engagers for neurological autoimmune diseases

Assessed scientific, clinical, commercial, and strategic attractiveness of the investment opportunity

Selected to found and lead the new company as CEO based on expertise and evaluation outcomes

Developed a comprehensive business plan supported by in-depth due diligence for a platform-based spin-off

Focus on first-in-class, double-armored CCR8 DNR TGFβ CAR-T cell therapies with demonstrated in vivo proof of concept against cold solid tumors

Built a strong network of pharma and legal experts to support venture formation and strategy

Established collaborations with Charles River, Catalent, and IQVIA

Secured pre-seed incubation at BioM/MaxL

Developed the business case and market opportunity assessment for a broad portfolio of innovative immuno-oncology assets

Focus areas included targeted multi-specific T-cell engagers addressing the tumor microenvironment and antibody-based radiotherapies

Delivered strategic insights and valuation inputs to support partnership and collaboration discussions

Developed the business case and optimal strategy, backed by thorough due diligence, for a new platform-based spin-off

Focus on a next-generation autologous, multivalent, HLA-independent CTAGs mRNA-loaded dendritic cell vaccine in Phase I/IIa for non-small cell lung cancer

Raised €750K in initial pre-seed funding to advance the venture

Developed the business case, supported by thorough due diligence, for a fragment-based small-molecule drug discovery spin-off

Successfully combined two innovative scientific teams to advance two next-generation TKI oncology programs at lead optimization stage

Secured €700K in pre-seed financing to drive further maturation of the pipeline

Conducted a comprehensive assessment for the Board of a family-office–backed biopharma company on the opportunity to spin out a portfolio of three immuno-modulatory mAbs

Evaluated scientific, strategic, and commercial potential across autoimmune and oncology indications at hit-to-lead stage

Developed recommendations for the optimal fundraising strategy to support the spin-out’s advancement

Built business case for CNS drug development

Supported fundraising efforts for Horizon Europe EIC Accelerator

Assessed spin-out opportunity for pre-IND MSC therapeutic programs in oncology and GVHD

Evaluated scientific and market potential, regulatory pathway, and competitive landscape

Defined refinancing and exit strategy targeting high-value return post–Phase I/IIa

Received mandate from its President, MIG investor, to assess financial opportunity to reschedule the company with new R&D options, after identifying the toxic profile of lead CPP against β-catenin, keeping the same platform model and 2 undruggable cancer stem cell breakthrough targets, or to sell its assets

Built new business plan, developing constrained peptides (stapled α-helix & macrocycles) against key PPIs in CSC pathways, after throughout auditing, competition analysis, and implementing an international KOLs scientific advisory board in peptide medicinal chemistry –, with new hits from new upgraded Y2-H/PD platforms and libraries, positively voted by Board of Directors

Proposed cash-based acquisition of identified start-up, spin-off from buoyant European academic center in peptide engineering, for fast-needed pivotal integration of seminal peptide chemistry (medicinal chemistry, computational design) and lead optimization know-how, and a large restructuring